## TER: Teradyne, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_20 2.7% below STRENGTH zone (4.0-10.0%); PEG 1.63 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($174.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 1, Bearish: 1)

**1. Is It Too Late To Consider Teradyne After Its 2025 AI and Automation Rally?**
- Source: Simply Wall Street | 20251217T030854 | Bearish | Relevance: 100%
- Teradyne's stock has rallied significantly in 2025, driven by its exposure to AI and automation. However, current valuation checks suggest the stock is overvalued, with a Discounted Cash Flow analysis indicating an 80.1% overvaluation and a Price-to-Earnings ratio of 68.0x, well above industry averages. The article encourages investors to use Simply Wall St's "Narratives" tool to align personal investment stories with financial forecasts to determine whether to buy, hold, or sell.

**2. 7 Stocks to Buy and Hold Forever**
- Source: InvestorPlace | 20251216T230906 | Bullish | Relevance: 97%
- Eric Fry identifies seven "Forever Stocks" that investors should consider as core holdings, representing 25% to 35% of their total portfolio. These stocks, including Teradyne, Block, Corning, Equinor, PayPal, Bristol-Myers Squibb, and Royalty Pharma, are highlighted for their long-term growth potential and strategic positioning in various industries despite short-term market fluctuations. The article delves into each company's unique advantages, such as Teradyne's robotics segment, Block's financial ecosystem, Corning's role in the AI boom, Equinor's energy position, PayPal's digital payment innovations, Bristol-Myers' pharmaceutical pipeline, and Royalty Pharma's royalty-based business model.

**3. Assessing Amkor Technology (AMKR) Valuation as Margin Pressures and Stalled Earnings Draw Investor Scrutiny**
- Source: Simply Wall Street | 20251217T050839 | Neutral | Relevance: 62%
- Amkor Technology (AMKR) is under investor scrutiny due to thin margins and stalled earnings, despite strong past share performance. Its current P/E ratio of 32.4x appears undervalued compared to peers and analyst growth expectations, suggesting potential upside if it meets profit forecasts. However, a Discounted Cash Flow model indicates the stock might be significantly overvalued at $40.28, painting conflicting pictures for investors.

**4. Mirador Capital Partners LP Lowers Stake in FormFactor, Inc. $FORM**
- Source: MarketBeat | 20251217T131058 | Neutral | Relevance: 60%
- Mirador Capital Partners LP significantly reduced its holdings in FormFactor, Inc. (NASDAQ:FORM) by 71.1% in the third quarter, selling 90,763 shares and retaining 36,847 shares valued at $1.34 million. Despite this, analysts have a consensus "Hold" rating on the stock with a $57 price target. Insider selling has also been noted, with corporate insiders selling 13,103 shares worth $671,473 over the last three months.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Goldman Sachs | $230 | $148 | +55% |
| 2025-12-02 | Stifel | $225 | $162 | +39% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Goldman Sachs | up | Buy |
| 2025-12-02 | Stifel | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.08M) |
| Sells | 6 ($0.76M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.3% (+2.1%)
- Blackrock Inc.: 8.4% (-7.2%)
- JPMORGAN CHASE & CO: 5.4% (+126.5%)
- State Street Corpora: 4.0% (+0.3%)
- Ameriprise Financial: 3.0% (+6.8%)

### Key Risks

1. High beta (1.85) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-3.1% 5d) with bearish MACD, trend may be turning.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.63 elevated, pricing in significant growth expectations. Forward P/E 37.1x attractive for 46% earnings growth. Quality metrics strong (margin 16%). Balance sheet: low leverage (D/E 0.46). Revenue growth strong at 23% YoY. Analyst sentiment positive (2 raises, avg +47%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $30.3B |
| Beta | 1.85 |
| 52W Range | $65.77 - $205.00 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.63 |
| Forward P/E | 37.1 |
| Current P/E | 54.1 |
| YoY Growth | 45.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 5.8% to 2.7% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.3pp (needs >4.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_20 - short-term weakness emerging. Outperforming sector by 3.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.71), momentum weakening. RSI neutral at 55. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.67% (CS: 67) | Neutral |
| RSI_14 | 55.0 | Neutral |
| MACD Histogram | -1.71 | Bearish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.115x | Above |
| vs SMA200 | 1.658x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $190.45
- **Stop Loss:** $174.07 (8.6% risk)
- **Target:** $206.83 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 57
- **Position Value:** $10,855.65
- **Portfolio %:** 10.86%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-28 (Est: $1.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.79 | $0.85 | +7.4% |
| 2025Q2 | $0.54 | $0.57 | +4.9% |
| 2025Q1 | $0.62 | $0.75 | +21.7% |
| 2024Q4 | $0.91 | $0.95 | +4.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*